3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
NIH
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Leukemia, Myeloid, Acute
35
Recurrence
27
Multiple Myeloma
27
Leukemia, Lymphocytic, Chronic, B-Cell
27
Lymphoma, Non-Hodgkin
25
Lymphoma
20
Neoplasms
16
Lymphoma, Large B-Cell, Diffuse
16
Lymphoma, B-Cell
15
Lymphoma, Follicular
14
Precursor Cell Lymphoblastic Leukemia-Lymphoma
13
Lymphoma, Mantle-Cell
13
Leukemia
13
Carcinoma, Non-Small-Cell Lung
13
Stomach Neoplasms
11
Ovarian Neoplasms
9
Pancreatic Neoplasms
8
Neoplasm Metastasis
8
Triple Negative Breast Neoplasms
7
Squamous Cell Carcinoma of Head and Neck
7
Head and Neck Neoplasms
7
Carcinoma, Renal Cell
7
Uterine Cervical Neoplasms
6
Myelodysplastic Syndromes
6
Melanoma
6
Lymphoma, B-Cell, Marginal Zone
6
Breast Neoplasms
6
Liposarcoma, Myxoid
5
Colorectal Neoplasms
5
Burkitt Lymphoma
5
Interventions
Robotic Surgical Procedures
2
N,1,4,4-tetramethyl-8-((4-(4-methylpiperazin-1-yl)phenyl)amino)-4,5-dihydro-1H-pyrazolo(4,3-h)quinazoline-3-carboxamide
2
pembrolizumab
1
isophosphamide mustard
1
fludarabine
1
atezolizumab
1
anetumab ravtansine
1
Octreotide
1
Imatinib Mesylate
1
Gemcitabine
1
Fentanyl
1
Cyclophosphamide
1
Cisplatin
1
AP 1903 reagent
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Thymoma
×
fludarabine
×
Clear all
NCT07598955
2026-05-20
SELECT-NK-THYM
Beijing Biotech
Phase 1/2
Recruiting
36 enrolled